Loading clinical trials...
Loading clinical trials...
A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Conditions
Interventions
Ramucirumab
Locations
13
United States
ImClone Investigational Site
Hollywood, Florida, United States
ImClone Investigational Site
Orlando, Florida, United States
ImClone Investigational Site
Chicago, Illinois, United States
ImClone Investigational Site
Marrero, Louisiana, United States
ImClone Investigational Site
Metairie, Louisiana, United States
ImClone Investigational Site
Baltimore, Maryland, United States
Start Date
August 1, 2008
Primary Completion Date
May 1, 2012
Completion Date
August 1, 2015
Last Updated
September 26, 2019
NCT06257264
NCT06964009
NCT06547840
NCT05080946
NCT07498829
NCT06503146
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions